menu search

RZLT / Rezolute (RZLT) Posts Positive Data From Congenital HI Study

Rezolute (RZLT) Posts Positive Data From Congenital HI Study
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism. Read More
Posted: Mar 24 2022, 15:03
Author Name: Zacks Investment Research
Views: 103126

RZLT News  

Rezolute (RZLT) Posts Positive Data From Congenital HI Study

By Zacks Investment Research
March 24, 2022

Rezolute (RZLT) Posts Positive Data From Congenital HI Study

Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperin more_horizontal


Search within

Pages Search Results: